Terutroban

Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC50 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties[1][2][3].

Product Specifications

CAS Number

[165538-40-9]

Product Name Alternative

S-18886

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Terutroban.html

Purity

99.84

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCC1=C2CC[C@@H](NS(=O)(C3=CC=C(Cl)C=C3)=O)CC2=CC=C1C

Molecular Formula

C20H22ClNO4S

Molecular Weight

407.91

Precautions

H315, H319, H335

References & Citations

[1]Gelosa P, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol. 2011 Mar;300 (3) :H762-8.|[2]Lesault PF, et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br J Clin Pharmacol.2011 Jun;71 (6) :844-851.|[3]Wang X, et al. Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2) -receptor antagonists. ACS Med Chem Lett. 2014 Jul 24;5 (9) :1015-20.